e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

144.86 +0.70 (+0.48%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

High Growth Momentum Stock NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Shows Strong Earnings Acceleration ↗

November 13, 2025

Discover NBIX, a top momentum stock with accelerating EPS growth of 64.5%, rising profit margins, and a perfect technical rating for a potential breakout.

Via Chartmill

Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile ↗

November 11, 2025

Neurocrine's Phase 2 trial of NBI-1070770 in major depressive disorder missed its main goal but showed good safety and strong Q3 financial results.

Via Benzinga

Zoom To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

November 11, 2025

Via Benzinga

Neurocrine Biosciences Inc (NASDAQ:NBIX) Fits the Affordable Growth Profile ↗

November 05, 2025

Neurocrine Biosciences (NBIX) offers strong growth, solid profitability, and a reasonable valuation, fitting an affordable growth investing strategy.

Via Chartmill

Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents a Compelling Value Investment Case ↗

October 30, 2025

Neurocrine Biosciences (NBIX) is a strong value stock with a debt-free balance sheet, high profitability, and solid growth, trading at a discount to its industry peers.

Via Chartmill

Earnings Scheduled For October 28, 2025 ↗

October 28, 2025

Via Benzinga

Earnings Scheduled For July 30, 2025 ↗

July 30, 2025

Via Benzinga

S&P 500 Tops 6,900 Ahead Fed Rate Move, Gold Reclaims $4,000: What's Moving Markets Wednesday? ↗

October 29, 2025

A powerful surge in AI-related stocks — led by a 9% advance in NVIDIA Corp. (NASDAQ:NVDA) over the past two sessions — propelled the S&P 500 above the 6,900 mark and lifted the Nasdaq 100 to 26,100...

Via Benzinga

Topics Economy Stocks

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Q3 2025 Earnings Top Estimates, Driving Stock Momentum ↗

October 28, 2025

Neurocrine Biosciences (NBIX) smashed Q3 2025 earnings estimates, with a 26% EPS beat and strong revenue growth driven by its flagship product INGREZZA®.

Via Chartmill

Neurocrine Bio Surges After Crushing Third-Quarter Expectations ↗

October 28, 2025

Shares of Neurocrine Biosciences raced ahead late Tuesday on better-than-expected third-quarter sales and earnings.

Via Investor's Business Daily

Examining the Future: Neurocrine Biosciences's Earnings Outlook ↗

October 27, 2025

Via Benzinga

What 13 Analyst Ratings Have To Say About Neurocrine Biosciences ↗

October 21, 2025

Via Benzinga

Demystifying Neurocrine Biosciences: Insights From 12 Analyst Reviews ↗

October 20, 2025

Via Benzinga

Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents an Affordable Growth Opportunity ↗

October 15, 2025

Discover Neurocrine Biosciences (NBIX), an affordable growth stock with strong financials, solid profit margins, and a promising pipeline in neuroscience treatments.

Via Chartmill

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Presents a Compelling Growth and Breakout Opportunity ↗

October 09, 2025

Discover Neurocrine Biosciences (NBIX), a neuroscience leader with strong growth, high profitability, and a positive technical breakout setup.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

September 25, 2025

Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session. The market value of their outstanding shares is at $87.2 million.

Via Benzinga

Neurocrine Biosciences Inc (NASDAQ:NBIX): An Affordable Growth Candidate in Biotechnology ↗

September 23, 2025

Neurocrine Biosciences (NBIX) offers solid growth and strong profitability at a reasonable valuation. This biotech stock fits the "affordable growth" strategy for long-term investors.

Via Chartmill

Where Neurocrine Biosciences Stands With Analysts ↗

September 22, 2025

Via Benzinga

Neurocrine Biosciences Inc (NASDAQ:NBIX) Screened as a Strong Growth Stock with Bullish Technical Setup ↗

September 17, 2025

Neurocrine Biosciences (NBIX) is a strong growth stock with accelerating revenue, high profitability, and a bullish technical breakout pattern.

Via Chartmill

Breaking Down Neurocrine Biosciences: 12 Analysts Share Their Views ↗

September 05, 2025

Via Benzinga

Neurocrine Biosciences Inc (NASDAQ:NBIX): A Prime GARP Candidate with Strong Growth and Reasonable Valuation ↗

September 02, 2025

Neurocrine Biosciences (NBIX) is a top GARP stock with strong growth, solid profitability, and a reasonable valuation in the biotech sector.

Via Chartmill

Neurocrine (NBIX) Q2 2025 Earnings Call Transcript ↗

August 05, 2025

Via The Motley Fool

Topics Earnings

Neurocrine (NBIX) Q2 Revenue Jumps 17% ↗

August 01, 2025

Via The Motley Fool

The Analyst Verdict: Neurocrine Biosciences In The Eyes Of 17 Experts ↗

July 31, 2025

Via Benzinga

Neurocrine Biosciences Inc (NASDAQ:NBIX): A Strong Affordable Growth Pick with Solid Fundamentals ↗

July 31, 2025

Neurocrine Biosciences (NBIX) offers strong growth, solid profitability, and fair valuation, making it a top pick for affordable growth investors.

Via Chartmill

Neurocrine Biosciences Inc (NASDAQ:NBIX) Beats Q2 2025 Earnings Estimates but Stock Drops 8.6% on Investor Concerns ↗

July 30, 2025

Neurocrine Biosciences (NBIX) beat Q2 2025 revenue and EPS estimates but stock fell 8.6% amid investor concerns over guidance. INGREZZA sales grew 17% YoY.

Via Chartmill

Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Strong Growth Stock with Breakout Potential ↗

July 28, 2025

Neurocrine Biosciences (NBIX) shows strong growth potential with solid fundamentals, high profitability, and a bullish technical breakout pattern in the biotech sector.

Via Chartmill

Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity ↗

July 10, 2025

Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal.

Via Investor's Business Daily

Topics Intellectual Property

A Glimpse Into The Expert Outlook On Neurocrine Biosciences Through 14 Analysts ↗

July 09, 2025

Via Benzinga

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - A Strong Growth Stock with Reasonable Valuation ↗

July 09, 2025

NEUROCRINE BIOSCIENCES (NBIX) offers strong growth, solid profitability, and reasonable valuation, making it an interesting candidate for investors seeking affordable growth stocks in the biotech...

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy